Main navigation
|
 |
| |
Medicines |
Main content
|
 printable version
Drug Alerts
RELATED LINKS
::
Drug Alert 124 [pdf 133kb]
A/H1N1 vaccination safety: new safety surveillance tool available
::
Drug Alert 123 [pdf 50kb]
Dextropropoxyphene-containing medicines to be withdrawn from European market
::
Drug Alert 122 [pdf 35kb]
Warning on purchase of antivirals without a prescription, including via the
Internet
::
Drug Alert 121 [pdf 147kb]
Marketing authorization of efalizumab in the European Union to be suspended due to
safety concerns
::
Drug Alert 120 [pdf 109kb]
Toremifene should not be used in patients at risk of QT-prolongation or other heart problems: recommendation from the European Medicines Agency
::
Drug Alert 119 [pdf 67kb]
Marketing authorization for rimonabant to be suspended across the European Union since the benefits of the medicine do not outweigh its risks
::
Drug Alert 118 [pdf 105kb]
Contaminant detected in heparin material of specified origin in the USA and in Germany;
serious adverse events reported; recall measures initiated
::
Drug Alert 117 [pdf 140kb]
Antimalarial chlorproguanil-dapsone (LapDap™) withdrawn following demonstration of
post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of
chlorproguanil-dapsone-artesunate (Dacart™) versus artemether-lumefantrine
(Coartem®) and confirmation of findings in a comparative trial
of LapDap™ versus Dacart ™
::
Drug Alert 116 [pdf 104kb]
Veralipride (The European Medicines Agency (EMEA) has issued a Press Release recommending the
withdrawal of the marketing authorization for all medicinal products containing veralipride).
::
Drug Alert 115 [pdf 164kb]
Vincristine (chemotherapeutic agent)
::
Drug Alert 114 [pdf 67kb]
(All batches of Viracept (nelfinavir) recalled from the European Market due to possible contamination with a genotoxic substance)
::
Drug Alert 113 [pdf 69kb]
(Oral nimesulide: marketing suspended in Ireland due to reports of liver failure)
::
Drug Alert 112 [pdf 76kb]
(Levaquin {levofloxacin} injection {25 mg/ml 20 ml vials, Batch Nos. 6CB5W00, 6CB6100;
Expiry February 2008}: product likely intended for black market use; public health hazard)
::
Drug Alert 111 [pdf 63kb]
(Cyclooxygenase-2 {COX-2} Inhibitor Medicines)
::
Drug Alert 110 [pdf 71kb]
{Counterfeit triple antiretroviral combination product (Ginovir 3D)
detected in Côte d’Ivoire}
::
Drug Alert 109 [pdf 121kb]
{Virologic failure in HIV patients treated with the combination of Didanosine, Lamivudine and Tenofovir}
::
Drug Alert 108 [pdf 109kb]
{Suspension of Manufacturing Licence held by Pan Pharmaceuticals Limited, Sydney}
::
Drug Alert 107 [pdf 73kb]
{Important safety update on lepirudin (Refludan) following reports
of fatal anaphylactic reactions}
::
Drug Alert 106 [pdf 74kb]
{Risk of serious hypersensitivity and skin reactions with parecoxib
sodium
The European Medicines Evaluation Agency (EMEA) has issued a public statement}
::
Drug Alert 105 [pdf 73kb]
{Olanzapine: associations with hyperglycemia resulting in diabetic
ketoacidosis and coma}
::
Drug Alert 104 [pdf 66kb]
{Rapid Alert Notification of a Quality Defect in Prednisolone-
Gentamicin (Pred-G) Eye Drops}
::
Drug Alert 103 [pdf 77kb]
{Nonacog alfa (Benefix) : Intensive post-marketing surveillance
and new clinical trials for additional data}
::
Drug Alert 102 [pdf 77kb]
{Voluntary withdrawal of Cerivastatin – Reports of Rhabdomyolysis}
::
Drug Alert 101 [pdf 78kb]
{Leflunomide – severe and serious hepatic reactions}
::
Drug Alert 100 [pdf 78kb]
{Infliximab (Remicade) – reports of tuberculosis infections}
|
|
